Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT02341560 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.

NCT NCT02341560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02341560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Lead sponsor
Quark Pharmaceuticals
Phase
Phase 2/3
Overall status
Terminated
Start date
February 24, 2016
Completion date
July 1, 2019
Enrollment
732 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

non arteritic anterior ischemic optic neuropathy